All Type of News
Korean drugs gain popularity
Homegrown medicines and technologies have been popular among multinational companies, according to the Korea Drug Research Association.
A number of leading officials from 50 drug giants were participated in the Kor...
HIRA to evaluate economic effectiveness of antihypertensive drugs next year
The Health Insurance Review and Assessment Service (HIRA) plans to evaluate the economic effectiveness of antihypertensive agents and other medicines between 2009 and 2013 and gradually readjust prices and exclude ite...
Health insurance to cover MSD’s Januvia tablets
The National Health Insurance Corporation said on November 11 that it finally agreed with MSD Korea to get Januvia (sitagliptin phosphate) listed in the national health insurance.
Under the agreement, Januvia 100 m...
Hanmi teams up with Kyungwon Medical over bone replacement products
Hanmi Pharm plans to sell a revolutionary bone substitute, PolyBone (calcium phosphate bone substitute) that regenerates bone after implantation and Optimum-S (bone cement) through a strategic alliance with Kyungwon M...
Drug makers, pharmacies to face off over OTC products
Controversy is expected to escalate between pharmaceutical firms and pharmacists over pharmaceutical firms' desire to sell over-the-counter products such as digestives and vitamins.
The government will push for a ...
Concerns rise among Korean drug makers
The domestic pharmaceutical sector is expected to face an inevitable blow as a court ruled that the Health Insurance Review and Assessment Service should make public the actually trade prices of 20 medicines in 35 hos...
New drug applications drop sharply
The number of application for the approval of new drugs has declined effective from November 5 as the Korea Food and Drug Administration increased its screening fee on that day.
According to the KFDA, there was no ...
Prevenar shown to reduce invasive pneumococcal disease in Korea’s young children
The routine use of Wyeth’s Prevenar (pneumococcal saccharide conjugated vaccine, adsorbed) helps protect against the seven pneumococcal serotypes causing the majority of disease in Korea, a local doctor said.
In a ...
Choong-wae completes Phase 2 trial of avanafil
Choong-wae Pharm says its has recently completed Phase 2 study of avanafil, Japan Tanabe’s phosphodiesterase type 5, or PDE5, inhibitor product candidate for the treatment of erectile dysfunction.
The trial took ni...
Pacific targets W20 billion in Meditoxin sales
Boosted by active demand of Meditoxin (Botulinum toxin) in domestic market, Pacific Pharm has set an ambitious goal of 20 trillion in its sales next year.
The company said that the goal represents a high increase ...
